Infliximab biosimilar - Amgen

Drug Profile

Infliximab biosimilar - Amgen

Alternative Names: ABP-710

Latest Information Update: 19 Oct 2016

Price : $50

At a glance

  • Originator Amgen
  • Class Anti-inflammatories; Anti-TNF monoclonal antibodies; Antipsoriatics; Antirheumatics; Monoclonal antibodies
  • Mechanism of Action Immunomodulators; Tumour necrosis factor alpha inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Rheumatoid arthritis
  • Phase I Ankylosing spondylitis; Crohn's disease; Plaque psoriasis; Psoriatic arthritis; Ulcerative colitis
  • Preclinical Inflammation; Rheumatic disorders

Most Recent Events

  • 19 Oct 2016 Phase-III development planned for Rheumatoid arthritis and development is ongoing for Inflammation in USA
  • 05 Oct 2016 Phase-III clinical trials in Rheumatoid arthritis (Adjunctive treatment) in Hungary (IV) (EudraCT2014-004704-29)
  • 03 Oct 2016 Phase-III clinical trials in Rheumatoid arthritis (Adjunctive treatment) in Spain (IV) (EudraCT2014-004704-29)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top